|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
The World Market for Addiction Disorders, 2009 - 2016
|
|
The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.
The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.
The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.
Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.
Objectives of Report
The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Report Highlights Include:
- The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
- Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
- Review of epidemiological, aetiological, and demographic data for addiction disorders
- Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product development
- Critical evaluation of leading addiction pharmacotherapies
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by addiction area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for novel candidates
- Market insights for product development and drug promotion
What you can learn from this report:
- Which addiction therapies are the current and potential future market leaders
- How companies are reformulating products for addiction indications
- Which premarket addiction pharmacotherapies are identified as high-value products
- Which companies are developing drugs for addiction disorders
- Sales predictions to 2016 for addiction pharmacotherapies
- What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
- Which addiction subsectors could be niche market opportunities
- What the future outlook holds for addiction pharmacotherapies
- Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
Which molecules and compounds are main R&D clusters for dependency disorders
- Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025
Report Contains:
- Detailed survey and analysis of the current and future global addiction disorder market
- Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
- Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
- Market analysis and insight of key addiction pharmacotherapies and pipelines
- Market value predictions of individual marketed products to 2016
Insight and trend analysis of pipeline products for addiction disorders
- Review of promising pipeline products and potential market opportunities
- Extensive coverage of the R&D pipeline for addiction disorders
- Guide to leads for potential licensing opportunities
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
